+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Therapy - Global Strategic Business Report

  • PDF Icon

    Report

  • 411 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 338434

Quick Summary:

Unlock the transformative potential of the gene therapy market with our meticulously curated and comprehensive market research report. Over the next eight years, significant growth is projected, with the global market estimated to soar from US$1.2 Billion in 2022 to US$5.9 Billion by 2030. Crucial areas such as viral and non-viral segments are analyzed meticulously, showcasing potential trends and opportunities you cannot afford to miss as an industry leader.

Breaking into geographic market analysis, the report provides a granular overview of key regions. These include the significant U.S market, projected growth in major economies like China, Japan, Canada, and Germany. Combined with competitive insights from Industry Leaders, such as Amgen Inc, Biogen, and Gilead Sciences, Inc., this report delivers a 360-degree view to understanding, entering, or expanding in the Gene Therapy market. With detailed insights, expert analysis, and customizable peer-to-peer updates, this market research report is your road map to success.

Global Gene Therapy Market to Reach $5.9 Billion by 2030

The global market for Gene Therapy estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$5.9 Billion by 2030, growing at a CAGR of 22.4% over the analysis period 2022-2030. Viral, one of the segments analyzed in the report, is projected to record 22.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Non-Viral segment is estimated at 20.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $628.2 Million, While China is Forecast to Grow at 28.8% CAGR

The Gene Therapy market in the U.S. is estimated at US$628.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 28.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 19.8% and 21.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 21.5% CAGR.

Select Competitors (Total 154 Featured)

  • Amgen, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • BioMarin Pharmaceutical, Inc.
  • AnGes, Inc.
  • Amicus Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Advantagene, Inc.
  • Biogen, Inc.
  • Abeona Therapeutics
  • Aptah
  • Avrobio
  • Arbor Biotechnologies, Inc.
  • Biocardia, Inc.

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Gene Therapy Market

What is the estimated value of the Gene Therapy Market?

The Gene Therapy Market was estimated to be valued at $1.2 Billion in 2022.

What is the growth rate of the Gene Therapy Market?

The growth rate of the Gene Therapy Market is 22.0%, with an estimated value of $5.9 Billion by 2030.

What is the forecasted size of the Gene Therapy Market?

The Gene Therapy Market is estimated to be worth $5.9 Billion by 2030.

Who are the key companies in the Gene Therapy Market?

Key companies in the Gene Therapy Market include Amgen, Inc., Alnylam Pharmaceuticals, Inc., Bionomics Ltd., BioMarin Pharmaceutical, Inc., AnGes, Inc., Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., bluebird bio, Inc., Advantagene, Inc. and Biogen, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • A Prelude to Gene Therapy
  • Classification of Gene Therapies
  • COVID-19 Causes Gene Therapy Market to Buckle & Collapse
  • COVID-19 Impact on Different Aspects of Gene Therapy
  • Manufacturing & Delivery
  • Research & Clinical Development
  • Commercial Operations & Access
  • Managing Derailed Operations
  • Focus on Clinical Development Programs
  • Targeting Manufacturing & Delivery Strategies
  • Securing Supplies
  • Remote Working
  • Gene Therapy Set to Witness Rapid Growth Post COVID-19
  • Gene Therapy - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • By Vector Type
  • VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET
  • Adeno-Associated Virus Vectors
  • Lentivirus
  • NON-VIRAL VECTORS TO WITNESS FASTER GROWTH
  • US and Europe Dominate the Gene Therapy Market
  • Oncology Represents the Largest Indication for Gene Therapy
  • Market Outlook
  • WORLD BRANDS
2. FOCUS ON SELECT PLAYERS
  • Recent Market Activity
  • Select Innovations
3. MARKET TRENDS & DRIVERS
  • Availability of Novel Therapies Drive Market Growth
  • Select Approved Gene Therapy Products
  • Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
  • Lentiviral Vectors Witness Increasing Interest
  • Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • Compelling Level of Technology & Innovation to Ignite Gene Therapy
  • Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases
  • Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine
  • M&As Rampant in Gene Therapy Space
  • Gene Therapy Deals: 2018 and 2019
  • Emphasis on Formulating Robust Regulatory Framework
  • Strong Gene Therapy Pipeline
  • Gene Therapy: Phase III Clinical Trials
  • OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR
  • Growing Funding for Gene Therapy Research
  • Market Issues & Challenges
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 3: World 13-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 6: World 13-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 9: World 13-Year Perspective for Non-Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 12: World 13-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 15: World 13-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 18: World 13-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 21: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2023 & 2030
  • TABLE 22: World Gene Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 25: USA 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 28: USA 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 31: Canada 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 34: Canada 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • JAPAN
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 37: Japan 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 40: Japan 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • CHINA
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 43: China 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 46: China 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • EUROPE
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 49: Europe 13-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2023 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 52: Europe 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 55: Europe 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • FRANCE
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 58: France 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 61: France 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • GERMANY
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 64: Germany 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 67: Germany 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 70: Italy 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 73: Italy 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • UNITED KINGDOM
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 76: UK 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 79: UK 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 81: Rest of Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 82: Rest of Europe 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 85: Rest of Europe 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • ASIA-PACIFIC
  • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 88: Asia-Pacific 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 91: Asia-Pacific 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
  • REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 93: Rest of World Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 94: Rest of World 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2023 & 2030
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • TABLE 97: Rest of World 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • BioMarin Pharmaceutical, Inc.
  • AnGes, Inc.
  • Amicus Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Advantagene, Inc.
  • Biogen, Inc.
  • Abeona Therapeutics
  • Aptah
  • Avrobio
  • Arbor Biotechnologies, Inc.
  • Biocardia, Inc.